Mengis Capital Management Inc. increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 7,559 shares of the company’s stock after buying an additional 160 shares during the period. Eli Lilly and Company comprises 1.3% of Mengis Capital Management Inc.’s holdings, making the stock its 18th largest position. Mengis Capital Management Inc.’s holdings in Eli Lilly and Company were worth $6,697,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in LLY. International Assets Investment Management LLC boosted its stake in shares of Eli Lilly and Company by 87,091.7% during the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company’s stock worth $11,041,631,000 after acquiring an additional 12,448,888 shares during the last quarter. Swedbank AB purchased a new position in Eli Lilly and Company during the first quarter valued at $932,797,000. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.6% during the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after purchasing an additional 1,133,810 shares during the period. Pathway Financial Advisers LLC increased its position in Eli Lilly and Company by 92,759.9% in the third quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company’s stock worth $905,774,000 after buying an additional 1,021,287 shares in the last quarter. Finally, Wulff Hansen & CO. raised its stake in shares of Eli Lilly and Company by 90,438.0% in the second quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after buying an additional 936,033 shares during the period. Institutional investors own 82.53% of the company’s stock.
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.13% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Research Report on LLY
Eli Lilly and Company Trading Down 1.6 %
Shares of NYSE LLY opened at $818.79 on Wednesday. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market cap of $777.29 billion, a price-to-earnings ratio of 88.52, a PEG ratio of 3.15 and a beta of 0.43. The business’s 50 day moving average price is $891.02 and its 200-day moving average price is $870.71.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. On average, sell-side analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
- 3 Small Caps With Big Return Potential
- Is Palantir’s AI Edge Enough to Justify Its Price?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.